Related Experiment Video
Updated: Jul 31, 2025
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.2K
Early endometrial carcinoma: Experience and outcomes
Priyanka Goel1, Vikram Singh1, Rakesh Sharma1
1Department of Departments of Surgical Oncology, Radiation Oncology, Medical Oncology and Pathology, Homi Bhabha Cancer Hospital, Sangrur, Punjab, India.
Journal of Cancer Research and Therapeutics
|May 6, 2023
Summary
This study analyzed endometrial carcinoma (EC) outcomes in rural India, finding a 90.6% three-year survival rate. Risk stratification and dedicated cancer center care improved patient outcomes.
Area of Science:
- Gynecologic Oncology
- Cancer Epidemiology
- Clinical Outcomes Research
Background:
- Endometrial carcinoma (EC) data from India, particularly rural regions, is notably scarce.
- Understanding outcomes in diverse populations is crucial for refining global treatment strategies.
Purpose of the Study:
- To retrospectively analyze the demography, histopathology, treatment, and outcomes of endometrial carcinoma patients treated at a peripheral cancer center in rural Punjab, India.
- To evaluate the applicability of the European Society for Medical Oncology (ESMO) risk stratification in this patient cohort.
Main Methods:
- Retrospective analysis of 98 Stage I and II EC patients with endometrioid histology (January 2015 - April 2020).
- Utilized FIGO 2009 staging and the new ESMO risk group classification for patient stratification.
- Data collected included demography, histopathology, surgical staging, adjuvant radiotherapy (RT), and patient outcomes.
Main Results:
- Median patient age was 60 years; 42.0% fell into the intermediate risk (IR) group per ESMO classification.
- 46.7% underwent complete surgical staging, and 50.5% received adjuvant RT.
- With a median follow-up of 27 months, the study observed 1 locoregional and 2 distant recurrences, with 8 total deaths, yielding a 3-year overall survival of 90.6%.
Conclusions:
- Adjuvant treatment decisions in endometrial cancer are guided by risk group stratification.
- Treatment at a dedicated cancer center facilitates better surgical staging and risk stratification, potentially leading to improved outcomes.
- The higher prevalence of IR histology in this cohort warrants further investigation compared to existing literature.
